Full Press Release Details
Purple Biotech Regains Compliance with Nasdaq
Minimum Bid Price Requirement
REHOVOT, Israel, March 17, 2026 - Purple
Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation
immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced that it received confirmation
from the Listing Qualifications Department of The Nasdaq Stock Market LLC (the "Listing Qualifications Department") that
the Company had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing
on The Nasdaq Capital Market ("Nasdaq"), and is now compliant with applicable listing standards for continued Nasdaq listing.
To regain compliance with Nasdaq Listing Rule 5550(a)(2), the Company was required to maintain a minimum closing bid price for the American
Depositary Shares (the "ADSs") of $1.00 per share or more for at least 10 consecutive business days, which was achieved on
About Purple Biotech
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage
company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity. The Company
is focused on advancing its lead program, CAPTN-3 - a platform of masked tri-specific antibodies that simultaneously target tumors while
engaging both T cells and NK cells. Capping technology confines immune activation to the tumor microenvironment, significantly expanding
the therapeutic window compared to conventional T-cell engagers. The platform's lead candidate, IM1240, is advancing toward the
clinic, and its second candidate, IM1305, is in preclinical development. The Company's pipeline also includes additional clinical-stage
assets, for which further development is pending partnering or investment, including CM24, a CEACAM1-blocking antibody that demonstrated
improved outcomes across all efficacy endpoints in a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma, and NT219, a
dual IRS1/2 and STAT3 inhibitor in a Phase 2 study for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head
and neck. The Company is headquartered in Rehovot, Israel. For additional information about the Company, please visit: https://purple-biotech.com
Forward-Looking Statements and Safe Harbor Statement
Certain statements in this press release that
are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that
are not statements of historical fact, and may be identified by words such as "believe", "expect", "intend",
"plan", "may", "should", "could", "might", "seek", "target",
"will", "project", "forecast", "continue" or "anticipate" or their negatives
or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters.
You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking
statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of
assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may
cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include,
among others, risks relating to: the plans, strategies and objectives of management for future operations; product development for NT219,
CM24, IM1240 and IM1305; the process by which such early stage therapeutic candidates could potentially lead to an approved drug product
is long and subject to highly significant risks, particularly with respect to a joint development collaboration; the fact that drug development
and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize
our pharmaceutical products; the expense, length, progress and results of any clinical trials; the impact of any changes in regulation
and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order
to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator
of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate;
the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market;
the introduction of competing products; patents obtained by competitors; dependence on the effectiveness of our patents and other protections
for innovative products; our ability to obtain, maintain and defend issued patents; the commencement of any patent interference or infringement
action against our patents, and our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure
to litigation, including patent litigation, and/or regulatory actions, and other factors that are discussed in our Annual Report on Form
20-F for the year ended December 31, 2024, as such factors may be updated from time to time in our other filings with the U.S. Securities
and Exchange Commission ("SEC"), including our cautionary discussion of risks and uncertainties under "Risk Factors"
in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially
from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this
press release speaks only as of the date which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking
statement or other information contained herein, whether as a result of new information, future events or otherwise, except as required
by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available
on the SEC's website, https://www.sec.gov.